Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analysts collectively rate Eyepoint Pharmaceuticals “Hold.” Of 11 firms, six recommend holding, four recommend buying and one recommends selling; the average 12-month price target is $25.70, though recent targets have been sharply reduced.
• EYPT shares opened at $4.57, down 4.6%. The stock is near its 12-month low of $3.95 and well below its 12-month high of $19.11, while its 50-day and 200-day moving averages are $10.97 and $12.85, respectively.
• The company reported a quarterly loss of $1.09 per share, missing the $1.01 consensus estimate, despite revenue of $0.51 million exceeding expectations. Institutional investors and hedge funds own 99.41% of the stock.

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned an average rating of "Hold" from the eleven research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $25.70.

A number of equities research analysts have weighed in on the company. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday. Jefferies Financial Group reduced their price objective on shares of Eyepoint Pharmaceuticals to $8.00 and set a "buy" rating for the company in a research report on Monday, August 17th. Stifel Nicolaus began coverage on shares of Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a "buy" rating and a $40.00 price objective for the company. Citigroup dropped their target price on shares of Eyepoint Pharmaceuticals to $17.00 and set a "buy" rating on the stock in a research report on Tuesday, August 18th. Finally, TD Cowen cut shares of Eyepoint Pharmaceuticals from a "buy" rating to a "hold" rating and reduced their price target for the stock from $20.00 to $4.00 in a report on Wednesday.

Institutional Trading of Eyepoint Pharmaceuticals

Several large investors have recently made changes to their positions in EYPT. Rhumbline Advisers boosted its holdings in Eyepoint Pharmaceuticals by 11.0% in the second quarter. Rhumbline Advisers now owns 96,280 shares of the company's stock worth $906,000 after acquiring an additional 9,548 shares in the last quarter. American Century Companies Inc. raised its position in shares of Eyepoint Pharmaceuticals by 57.8% during the second quarter. American Century Companies Inc. now owns 67,612 shares of the company's stock worth $636,000 after purchasing an additional 24,752 shares during the period. Invesco Ltd. lifted its holdings in shares of Eyepoint Pharmaceuticals by 199.8% in the 2nd quarter. Invesco Ltd. now owns 128,772 shares of the company's stock worth $1,212,000 after purchasing an additional 85,824 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock worth $112,000 after purchasing an additional 1,177 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its position in Eyepoint Pharmaceuticals by 9.7% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company's stock valued at $63,988,000 after purchasing an additional 600,000 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

Eyepoint Pharmaceuticals Stock Down 4.6%

EYPT stock opened at $4.57 on Friday. The firm has a market cap of $393.98 million, a price-to-earnings ratio of -1.22 and a beta of 1.63. Eyepoint Pharmaceuticals has a 12-month low of $3.95 and a 12-month high of $19.11. The company's fifty day simple moving average is $10.97 and its 200 day simple moving average is $12.85.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.08). The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. Research analysts expect that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source